nicotine and ondansetron
nicotine has been researched along with ondansetron in 28 studies
Research
Studies (28)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (35.71) | 18.2507 |
2000's | 9 (32.14) | 29.6817 |
2010's | 8 (28.57) | 24.3611 |
2020's | 1 (3.57) | 2.80 |
Authors
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gordon, JC; Gurley, D; Lanthorn, T; Loch, J; Mack, RA; Macor, JE; Mullen, G; Tran, O; Wright, N | 1 |
Keserü, GM | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Jia, L; Sun, H | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Ito, T; Omoya, H; Yoshida, N | 1 |
Costall, B; Jones, BJ; Kelly, ME; Naylor, RJ; Onaivi, ES; Tyers, MB | 1 |
Everitt, BJ; Muir, JL; Robbins, TW | 1 |
Allison, K; Arnold, B; Greenshaw, AJ; Ivanová, S; Paetsch, PR; Paslawski, T | 1 |
Herberg, LJ; Montgomery, AM; Rose, IC | 1 |
Apfelbaum, JL; Lichtor, JL; Zacny, JP; Zaragoza, JG | 1 |
Bhattacharya, SK; Chakrabarti, A; Glover, V; Sandler, M | 1 |
Hajek, P; West, R | 1 |
Ise, Y; Misawa, M; Mori, T; Suzuki, T | 1 |
Greenshaw, AJ; Ivanová, S | 1 |
Cheng, Q; Dergacheva, O; Gorini, C; Jameson, HS; Kamendi, HW; McIntosh, JM; Mendelowitz, D; Wang, X | 1 |
Grady, SR; Marks, MJ; O'Neill, HC; Ortiz, NC | 1 |
Iha, HA; Kunisawa, N; Matsubara, N; Nomura, Y; Ohno, Y; Onishi, M; Shimizu, S | 1 |
Buzoianu, AD; Feng, L; Lafuente, JV; Li, C; Muresanu, DF; Nozari, A; Sharma, A; Sharma, HS; Sharma, S; Sjöqvisst, PO; Tian, ZR; Wiklund, L; Zhang, Z | 1 |
Reviews
1 review(s) available for nicotine and ondansetron
Article | Year |
---|---|
Nicotine neurotoxicity exacerbation following engineered Ag and Cu (50-60 nm) nanoparticles intoxication. Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron.
Topics: Animals; Antioxidants; Brain; Brain Edema; Humans; Nanoparticles; Neuroprotection; Neuroprotective Agents; Nicotine; Ondansetron; Serotonin 5-HT3 Receptor Antagonists | 2023 |
Trials
2 trial(s) available for nicotine and ondansetron
Article | Year |
---|---|
Effects of 5-hydroxytryptamine3 antagonist, ondansetron, on cigarette smoking, smoke exposure, and mood in humans.
Topics: Adult; Affect; Double-Blind Method; Female; Humans; Male; Nicotine; Ondansetron; Prospective Studies; Smoking; Smoking Cessation; Tobacco Smoke Pollution | 1993 |
Randomised controlled trial of ondansetron in smoking cessation.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Ondansetron; Serotonin Antagonists; Smoking Cessation; Substance Withdrawal Syndrome | 1996 |
Other Studies
25 other study(ies) available for nicotine and ondansetron
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cell Membrane; Hippocampus; Indoles; Inhibitory Concentration 50; Intestine, Small; Ligands; Membrane Potentials; Mice; Nicotinic Agonists; Oocytes; Protein Binding; Rats; Receptors, Nicotinic; Serotonin Antagonists; Structure-Activity Relationship; Tropisetron; Xenopus | 2001 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Topics: Animals; Antiemetics; Azepines; Cisplatin; Copper; Copper Sulfate; Dogs; Female; Ferrets; Gastric Emptying; Imidazoles; Indazoles; Male; Nicotine; Ondansetron; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin Antagonists; Shrews | 1992 |
Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse.
Topics: Animals; Cocaine; Ethanol; Exploratory Behavior; Illicit Drugs; Imidazoles; Male; Mice; Nicotine; Ondansetron; Rats; Rats, Inbred Strains; Serotonin Antagonists; Social Behavior; Substance Withdrawal Syndrome | 1990 |
Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron.
Topics: Amphetamine; Animals; Attention; Cerebral Cortex; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Male; Nicotine; Ondansetron; Parasympathetic Nervous System; Physostigmine; Prosencephalon; Rats; Reaction Time | 1995 |
5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Granisetron; Haloperidol; Indoles; Male; Motor Activity; Nicotine; Ondansetron; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Time Factors; Tropanes; Tropisetron | 1995 |
The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission.
Topics: Animals; Dextroamphetamine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Hypothalamus; Male; Nicotine; Ondansetron; Rats; Receptors, Serotonin; Reward; Self Stimulation; Serotonin Antagonists; Synaptic Transmission | 1993 |
Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety.
Topics: Animals; Anxiety; Brain; Brain Chemistry; Cannabis; Ethanol; Isatin; Isoenzymes; Lorazepam; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morphine; Nicotine; Ondansetron; Rats; Rats, Wistar; Substance Withdrawal Syndrome | 1995 |
Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron.
Topics: Animals; Conditioning, Psychological; Male; Mecamylamine; Nicotine; Nicotinic Antagonists; Ondansetron; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Substance Withdrawal Syndrome | 1997 |
Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron.
Topics: Animals; Conditioning, Operant; Dopamine Antagonists; Haloperidol; Male; Mecamylamine; Muscarinic Antagonists; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Ondansetron; Rats; Rats, Sprague-Dawley; Scopolamine; Self Stimulation; Serotonin Antagonists; Ventral Tegmental Area | 1997 |
Abolishment of serotonergic neurotransmission to cardiac vagal neurons during and after hypoxia and hypercapnia with prenatal nicotine exposure.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Animals, Newborn; Conotoxins; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Agents; Female; Heart; Hypercapnia; Hypoxia; In Vitro Techniques; Male; Neurons; Nicotine; Nicotinic Antagonists; Ondansetron; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Serotonin; Serotonin Antagonists; Synaptic Transmission; Vagus Nerve; Valine | 2009 |
Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Topics: Animals; Benzazepines; Dose-Response Relationship, Drug; Female; Genotype; Hexamethonium; Hypothermia; Inhibitory Concentration 50; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Motor Activity; Mutation; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Ondansetron; Quinoxalines; Receptors, Nicotinic; Receptors, Serotonin, 5-HT3; Varenicline | 2012 |
Serotonergic modulation of nicotine-induced kinetic tremor in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Fenclonine; Humans; Male; Mice; Nicotine; Ondansetron; Piperazines; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin; Ritanserin; Serotonin Antagonists; Serotonin Receptor Agonists; Tremor | 2017 |